menu
    • menu
    [{"orgOrder":0,"company":"AcedrA BioPharmaceuticals","sponsor":"TaiMed Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AcedrA BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AcedrA BioPharmaceuticals \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AcedrA BioPharmaceuticals \/ AcedrA BioPharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by AcedrA BioPharmaceuticals

    Menu

    AcedrA BioPharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AcedrA BioPharmaceuticals

                            Saudi Arabia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            AcedrA BioPharmaceuticals

                            Saudi Arabia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : TaiMed Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiMed Partners with AcedrA To Commercialize Trogarzo® in MENA Region

                            Details : AcedrA will register, promote, and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor, for treating HIV-1 infection in the MENA region.

                            Product Name : Trogarzo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 18, 2024

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : TaiMed Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth